Vor Biopharma is a clinical-stage company that focuses on engineered hematopoietic stem cell therapies for cancer patients. Its main product candidate, VOR33, targets acute myeloid leukemia and other hematological malignancies by eliminating CD33 protein. The company's eHSCs targeted therapies offer various treatments for blood cancers and it also collaborates with Akron BioProducts to develop and manufacture cGMP nucleases.